- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01630720
Vitamin Therapy in JGH Patients
There is a high prevalence of hypovitaminosis C and D in our hospital and other acute-care hospitals. Since the correction of these presumed deficiency states is simple, safe and inexpensive, their documented or suspected presence would normally be considered sufficient indication to correct them. However, the common practice is to ignore them. Identification of specific measurable medical consequences of hypovitaminosis C or D would provide a stronger case to treat or prevent in-hospital vitamin deficiency states.
Biochemical deficiencies of vitamin C and D have both been linked to mood disturbance, and hypovitaminosis C reportedly increases blood histamine concentrations.
We recently found that the provision of vitamin C (500 mg twice daily) but not vitamin D (1000 IU twice daily) promptly improved the average mood score of acutely hospitalized patients. We will now conduct a closely similar randomized clinical trial using a more adequate dose of vitamin D, namely 5000 IU/day for up to 10 days.
Study Overview
Status
Intervention / Treatment
Detailed Description
HYPOTHESIS:
Adequate vitamin C or vitamin D provision to mentally competent acutely hospitalized patients for 7 to 10 days will correct their biochemical deficiency, improve their mood, and (in the vitamin C-treated patients) reduce blood histamine concentrations.
PROTOCOL:
- Mentally competent patients fluent in English or French admitted to the surgical or medical units of the hospital will be offered participation.
- Plasma vitamin C and 25-hydroxyvitamin D, serum C-reactive protein, parathyroid hormone level (a measure of vitamin D adequacy) and blood histamine will be measured in participating patients prior to starting the treatment and after 7 to 10 days of treatment.
- Within 24 h prior to and within 24 after the 5-10 d treatment course the patient will complete the POMS-B, a validated one-page 30-item questionnaire that assesses mood and energy, and the Distress Thermometer. Patients followed only for the 5-10 d duration of the clinical trial.
- The chart will be reviewed for age, sex, diagnosis, and pertinent lab results.
- After the initial blood sample has been drawn and the questionnaire completed the patient will begin treatment either with vitamin C 500 mg twice daily or vitamin D 5000 IU daily; both vitamins will be prescribed by one of the collaborating physicians without knowledge of the person who recruits, assesses and follows the patient. Treatment assignment will be by coin toss.
7. The questionnaire and blood sampling will be repeated after 7 to 10 days of treatment (as determined by feasibility and the situation on the ward) or prior to discharge if discharge is going to occur before the full course of treatment.
8. Neither the patient nor the person who administers the questionnaires will know which patient receives vitamin C or D. The vitamin D and C tablets are distinguishable, so patients motivated to do so could figure out which vitamin they are being prescribed. Since both treatments are being used to correct deficiency diseases which are strongly suspected to affect mood, neither patients, nurses, nor the students following the patients have no basis to anticipate that one treatment will improve their mood more than the other one.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- acutely hospitalized in our hospital
- mentally competent
- judged likely to remain in hospital for at least the following 7 days
- fluent in French or English
Exclusion Criteria:
- presence of hypercalcemia
- receiving hemodialysis treatment
- critically ill
- unable to take medication by mouth
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: vitamin C
vitamin C 500 mg twice daily
|
vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
|
Active Comparator: vitamin D
vitamin D 5000 IU daily
|
vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mood
Time Frame: prior to and after 5-10 days of treatment
|
total mood disturbance score on the POMS-B (profile of mood states).
Durations of hospital stay are variable and often unpredictable.
The intended duration of therapy is 7 to 10 days of treatment, with baseline just prior to starting and outcome measurement recorded just after the final day of therapy.
The 7-10 day window is necessary and valid to account for vagaries in duration of hospital stay as well as the interfering effect of weekends when less staffing is available.
As in our prior published work, any treatment duration 5 days or longer is included as sufficient.
|
prior to and after 5-10 days of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood histamine concentration
Time Frame: prior to and after 5-10 days of treatment
|
Blood histamine concentration.
Durations of hospital stay are variable and often unpredictable.
The intended duration of therapy is 7 to 10 days of treatment, with baseline just prior to starting and outcome measurement recorded just after the final day of therapy.
The 7-10 day window is necessary and valid to account for vagaries in duration of hospital stay as well as the interfering effect of weekends when less staffing is available.
As in our prior published work, any treatment duration 5 days or longer is included as sufficient.
|
prior to and after 5-10 days of treatment
|
distress
Time Frame: prior to and after 5-10 days of treatment
|
the distress thermometer.
Durations of hospital stay are variable and often unpredictable.
The intended duration of therapy is 7 to 10 days of treatment, with baseline just prior to starting and outcome measurement recorded just after the final day of therapy.
The 7-10 day window is necessary and valid to account for vagaries in duration of hospital stay as well as the interfering effect of weekends when less staffing is available.
As in our prior published work, any treatment duration 5 days or longer is included as sufficient.
|
prior to and after 5-10 days of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Hypovitaminosis C and D
-
Hospices Civils de LyonCompleted
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Silvana De Giorgi; Davide Bizzoca; Angela NotarnicolaRecruitingHypovitaminosis DItaly
-
Madigan Army Medical CenterCompletedHypovitaminosis DUnited States
-
University of TromsoCompleted
-
Boston UniversityCompletedVitamin D Deficiency | Vitamin E Deficiency | Hypovitaminosis AUnited States
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Massachusetts General HospitalBio-Tech Pharmacal, Inc.CompletedHypovitaminosis DUnited States
-
Harokopio UniversityUniversity College Cork; FrieslandCampinaCompletedHypovitaminosis D | Deficiency of MicronutrientsGreece
-
Charles Drew University of Medicine and ScienceNational Institute on Minority Health and Health Disparities (NIMHD); Morehouse...CompletedHypovitaminosis DUnited States
-
Chulalongkorn UniversityUnknownVitamin D2 Supplementation in Vitamin D InsufficiencyThailand
Clinical Trials on vitamin C or vitamin D
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
University Hospital, AngersUnknownAlzheimer's Disease | Impaired Cognition | Gait ApraxiaFrance
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Shiraz University of Medical SciencesCompletedRestless Legs Syndrome | Kidney Failure, ChronicIran, Islamic Republic of
-
Khon Kaen UniversityNot yet recruiting
-
424 General Military HospitalRecruitingOsteoporosis, PostmenopausalGreece, France, Germany, Italy
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States